Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?

Pfizer reported stronger-than-expected second-quarter results, with revenue up 10% to $14.7 billion and adjusted EPS rising 30% to $0.78, driven by robust performance from its coronavirus vaccine Comirnaty (+96%), COVID-19 treatment Paxlovid (+70%), and new RSV vaccine Abrysvo, alongside established products and ongoing cost reductions. While the company faces near-term uncertainty from a volatile COVID franchise and upcoming patent expirations for key drugs like Eliquis, its long-term prospects are supported by a strong oncology pipeline, continued expense management targeting $7.2 billion in savings by 2027, and promising new product launches, making its current valuation of 8.3x forward P/E and 7% dividend yield attractive despite prior stock underperformance.

Analysis

Pfizer's second-quarter results demonstrated significant outperformance, with total revenue rising 10% year-over-year to $14.7 billion and adjusted EPS growing 30% to $0.78. This strength was driven by an unexpected resurgence in its coronavirus franchise, where Comirnaty sales grew 96% to $381 million and Paxlovid sales increased 70% to $427 million. Concurrently, the new RSV vaccine, Abrysvo, is gaining traction with $143 million in quarterly sales, while established products like Eliquis and Xtandi continue to contribute. The company is also realizing operational efficiencies, projecting $4.5 billion in net cost savings by year-end. Despite these positive results, significant uncertainties persist. The COVID-19 business remains highly unpredictable, and key revenue drivers, including Eliquis and Xtandi, face patent expirations in the coming years. However, the long-term outlook is supported by a strengthening oncology pipeline, a broader cost reduction plan aiming for $7.2 billion in savings by 2027, and the growth potential of new products. The stock's valuation appears compelling, with a forward price-to-earnings ratio of 8.3, substantially below the industry average of 15.9, complemented by a strong 7% forward dividend yield.

Key Decisions for Investors

• For long-term investors, the current valuation at a forward P/E of 8.3 and a 7% dividend yield may present an attractive entry point, despite near-term revenue volatility and recent stock underperformance.
• Monitor key catalysts that are critical to offsetting future patent cliffs, specifically the commercial ramp-up of new products like Abrysvo and clinical or regulatory milestones from the oncology pipeline.
• Acknowledge the unpredictable nature of the coronavirus franchise, which provided a significant Q2 boost but cannot be relied upon for consistent future performance, when assessing risk.
• Track the company’s progress towards its stated cost-saving targets of $4.5 billion by the end of this year and $7.2 billion by 2027, as achieving these efficiencies is fundamental to supporting margins and earnings growth.